Persistent Asset Partners Ltd purchased a new position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 22,330 shares of the company's stock, valued at approximately $663,000.
Other institutional investors have also modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in Immunocore in the 4th quarter worth about $25,000. Oppenheimer Asset Management Inc. bought a new position in Immunocore in the 1st quarter valued at $225,000. Tema Etfs LLC bought a new stake in shares of Immunocore during the fourth quarter worth $330,000. Virtus ETF Advisers LLC boosted its position in shares of Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock worth $340,000 after purchasing an additional 3,238 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in Immunocore by 22.2% in the fourth quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock valued at $557,000 after acquiring an additional 3,437 shares during the period. Institutional investors and hedge funds own 84.50% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. cut their price objective on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, April 14th. Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a research note on Saturday. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research note on Monday, June 2nd. Deutsche Bank Aktiengesellschaft started coverage on Immunocore in a research report on Tuesday, May 27th. They set a "buy" rating and a $65.00 target price on the stock. Finally, Oppenheimer increased their target price on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $58.00.
View Our Latest Stock Analysis on IMCR
Immunocore Price Performance
Immunocore stock opened at $31.89 on Tuesday. Immunocore Holdings PLC Sponsored ADR has a 12-month low of $23.15 and a 12-month high of $39.33. The stock has a market capitalization of $1.60 billion, a P/E ratio of -79.73 and a beta of 0.77. The firm's 50-day moving average is $34.02 and its two-hundred day moving average is $31.22. The company has a debt-to-equity ratio of 1.01, a current ratio of 5.89 and a quick ratio of 5.86.
Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The company had revenue of $130.65 million for the quarter, compared to analyst estimates of $122.96 million. During the same quarter last year, the firm posted ($0.23) earnings per share. The business's quarterly revenue was up 30.0% on a year-over-year basis. Equities analysts predict that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.
About Immunocore
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access